Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte‐colony‐stimulating factor: safety, efficacy, and graft performance-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte‐colony‐stimulating factor: safety, efficacy, and graft performance

Published:2016-09-16 Issue:12 Volume:56 Page:3055-3064
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Becker Petra¹,Schwebig Arnd²,Brauninger Susanne¹,Bialleck Heike¹,Luxembourg Beate¹,Schulz Miriam¹,Tsamadou Chrysanthi³,Wiesneth Markus³,Reinhardt Peter³,Mytilineos Joannis³,Seidl Christian¹,Gattu Sreekanth²,Kaliakina Natalia²,Singh Pritibha⁴,Schrezenmeier Hubert³,Seifried Erhard¹,Bonig Halvard¹⁵

Affiliation:

1. Institute for Transfusion Medicine and Immunohematology of Goethe University and German Red Cross Blood Donor ServiceFrankfurt am Main Germany

2. Hexal AGHolzkirchen Germany

3. Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Donor Service and University Hospital UlmUlm Germany

4. Novartis Pharma AGBasel Switzerland

5. Department of Medicine/HematologyUniversity of WashingtonSeattle Washington.

Funder

Hexal AG

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/trf.13853

Reference47 articles.

1. Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?

2. Update on biosimilars of granulocyte colony-stimulating factor – when no news is good news

3. Potential Cost Savings From Chemotherapy-Induced Febrile Neutropenia With Biosimilar Filgrastim and Expanded Access to Targeted Antineoplastic Treatment Across the European Union G5 Countries: A Simulation Study

4. G-CSF: filgrastim, lenograstim and biosimilars

5. Development of a new G-CSF product based on biosimilarity assessment

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience;Annals of Transplantation;2023-02-20

2. Is split‐dose better than single‐dose? Results of Turkish Stem Cell Coordination Center ( TURKOK ) donors in the era of rising biosimilar G‐CSF;Journal of Clinical Apheresis;2022-06-11

3. Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience;BioDrugs;2022-05

4. The safety and efficacy of hematopoietic stem cell mobilization using biosimilar filgrastim in related donors;International Journal of Hematology;2022-04-09

5. Superior physical and mental health of healthy volunteers before and five years after mobilized stem cell donation;Journal of Translational Medicine;2022-03-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3